Everything below concerns animal model. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
== Uses == The dominant use of perchlorates is as oxidizers in propellants for rockets, fireworks and highway flares. Of particular value is ammonium perchlorate composite propellant as a component of solid rocket fuel. In a related but smaller application, perchlorates are used extensively within the pyrotechnics industry and in certain munitions and for the manufacture of matches. Martian perchlorates might also be used to produce fuel on that planet. Perchlorate is used to control static electricity in food packaging. Sprayed onto containers it stops statically charged food from clinging to plastic or paper/cardboard surface. Niche uses include lithium perchlorate, which decomposes exothermically to produce oxygen, useful in oxygen "candles" on spacecraft, submarines, and in other situations where a reliable backup oxygen supply is needed. Potassium perchlorate has, in the past, been used therapeutically to help manage Graves' disease. It impedes production of the thyroid hormones that contain iodine. As perchlorate is generally a non-complexing anion and that its sodium salts is particularly soluble, it is commonly used as a background, or supporting, electrolyte in solution chemistry, electrophoresis, and electrochemistry. Although used as a powerful oxidizer in propulsive powders and explosives, quite surprisingly, the perchlorate anion is a weak oxidant in aqueous solution because of kinetics limitations severely hindering the electron transfer.
== Chemical and biochemical features == Taurine exists as a zwitterion H3N+CH2CH2SO−3, as verified by X-ray crystallography. The sulfonic acid has a low pKa ensuring that it is fully ionized to the sulfonate at the pHs found in the intestinal tract.
The Journal of Chromatographic Science (JCS) is a peer reviewed academic journal of chromatography. It is published by Oxford University Press. The Journal focuses on research papers describing practical and preparative applications and analytical methods relevant to a broad range of laboratory work. The editors-in-chief are Huba Kalász and Neil Danielson. According to the Journal Citation Reports, the journal has a 2020 impact factor of 1.618.
In the case of air pumps, diaphragm pumps are considered to be a type of pump that utilizes positive displacement. A simple diaphragm pump contains a chamber that acts like a springy diaphragm. When compressed, the air within the diaphragm gets expelled. When the diaphragm is decompressed, the chamber refills with air. A simple example for a diaphragm pump is a foot pump that requires the user to constantly step up and down on the pump to inflate something. Engine-driven tire pump Several companies developed engine-driven tire pumps in the brass era of the automobile. Reciprocating Pumps
Sources: en.wikipedia.org
=== Scotland to England in 2007 === On 29 April 2007, he began walking again at John o' Groats and arrived at Land's End on 8 June, having covered 900 miles (1,400 km) in 6 weeks. On the walk in Britain he visited 20 hospices and raised £10,000 for hospice through sales of his Beyond the Setting Sun book.
Luminol in an alkaline solution with hydrogen peroxide in the presence of iron or copper, or an auxiliary oxidant, produces 3-aminophtalate in an excited state, which exhibits chemiluminescence. The luminol reaction is
Founder and lately Teacher, Harmanli Refugee Camp Play School, Bulgaria. For services to the Humanitarian Support of Refugee Children in Bulgaria. Sadie Clasby-Jarrous. Founder and lately Manager, Harmanli Refugee Camp Play School, Bulgaria. For services to the Humanitarian Support of Refugee Children in Bulgaria. Timothy Robert Conibear. Founder, Waves for Change. For services to Young People Overseas. John David Crouch. Lately Technical Works Supervisor, British Embassy Mogadishu, Somalia. For services to the UK Government Overseas. Sophie Louise Dyer. Lately Counsellor, Trade Policy, British Embassy Tokyo, Japan. For services to Trade. Deborah Carol Edgington. Councillor for Tourism, Fuerteventura, Canary Islands, Spain. For services to British Nationals in Fuerteventura. Richard John Field. Independent Voluntary and Charity Worker in rural Uganda. For services to Young People and Health in Uganda. Kelly Teresa Fisher. Professional Pool, Snooker and English Billiards player. For services to Sport. Nigel James Fossey. Principal, The Sultan's School, Oman and formerly Headmaster, King´s College School, Panama. For services to British Education Overseas. Lowri Mai Griffiths. Head, Ocean Policy Unit, Legal Directorate, Foreign, Commonwealth and Development Office. For services to Ocean Protection. Joanne Margaret Hare. Deputy Director, Foreign, Commonwealth and Development Office. For services to National Security. Elizabeth Ann Haydon. Head, Harrow International School, Hong Kong. For services to British Education in the UK and Hong Kong. Frank Alexander Menzies-Hearn.
== Volunteers == CLSI relies on more than 2,000 volunteers. Volunteers and mentors also collaborate with CLSI's Global Health Partnerships to help establish laboratory quality management systems in resource-limited countries.
The adrenergic receptors were discovered Henry Hallett Dale in 1906 and the α- and β-adrenergic receptors were differentiated by Raymond P. Ahlquist in 1948. In 1967, the β-adrenergic receptors were further differentiated into the β1- and β2-adrenergic receptors by Alonzo M. Lands. The first beta blocker to be developed was dichloroisoprenaline, based on structural modification of the β-adrenergic receptor agonist isoprenaline (isoproterenol). It was described by C. E. Powell and I. H. Slater in 1958. However, dichloroisoprenaline had significant partial agonism and sympathomimetic activity and hence was not a pure antagonist. James Black and John Stephenson described pronethalol (nethalide; ICI-38,174; Alderlin) as a purely antagonistic beta blocker in 1962. But pronethalol suffered from off-target activity and associated side effects and toxicity. As such, it did not enter widespread use and was soon discontinued. In 1964, Black and colleagues published on propranolol (ICI-45,520; Inderal), which did not have the problems of earlier beta blockers. It was introduced for medical use under the brand name Inderal the same year and became the first widely used beta blocker. Since the introduction of propranolol, there have been three generations of beta blockers with different pharmacological properties, with numerous beta blockers having been developed and introduced for medical use.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.